Boeing CEO pay climbs while stock drops

Boeing stock might be down 58% from its all-time high in March 2019, but you wouldn't know it by looking at the company's CEO compensation history.

Despite Boeing's struggles, the airplane manufacturer has increased its CEO compensation by 129% since 2019, from $14.3 million up to $32.8 million in 2023.

Current CEO Dave Calhoun is stepping down at the end of 2024, but Reuters reported that his potential retirement payout was worth up to $44 million according to a 2023 regulatory filing.

Departing Boeing CEO gets nearly $33 million in 2023 total compensation

Current CEO Dave Calhoun is stepping down at the end of 2024, but Reuters reported that his potential retirement payout was worth up to $44 million according to a 2023 regulatory filing.

More Business

See all Business

Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

J. Edward Moreno1h

Claire Yubin Oh

The apex operator

SharkNinja hit an all-time high this week, as its killer growth streak continues

The viral appliance maker’s sales have more than quadrupled since 2018.

Surreal image of great white shark swimming in bedroom

Claire Yubin Oh

in this econemy?

2/12/26

Van Leeuwen, America’s fastest-growing dessert chain, is looking to expand abroad

The boutique ice cream chain is looking to open at least 300 new shops in South Korea over the next decade.

J. Edward Moreno

2/10/26

Hims built a boundary-pushing health business. Now the legal risks are catching up.

Hims is close to trading as if it never began selling GLP-1s.

Nate Becker2/7/26

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration.

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims & Hers Comms on X

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.